BridgeBio’s Infigratinib Delivers 1.8 cm/Year Growth Boost in Phase 3 Trial
BridgeBio Pharma reported that its Phase 3 PROPEL-3 trial in 135 pediatric achondroplasia patients met the primary endpoint, showing a mean 1.8 cm/year increase in annualized height velocity versus placebo over 12 months. The study also confirmed a safety profile consistent with earlier phases, with no new grade 3 or higher adverse events.
1. PROPEL-3 Trial Design and Results
BridgeBio Pharma’s global Phase 3 PROPEL-3 study enrolled 135 children aged 2–12 with achondroplasia, randomizing participants to daily oral infigratinib or placebo. After 12 months, the treatment arm achieved a mean annualized height velocity increase of 1.8 cm/year over placebo, surpassing the trial’s primary endpoint and demonstrating robust bone growth acceleration.
Related News
MA
Chargebacks911 Partners with acceptcards to Reduce Chargebacks as UK Card Use Tops £1 Trn
MA•
NBTX
Nanobiotix Halts Trading to Finalize €75 M Follow-On Offering Pricing
NBTX•
ODV
Osisko Development Raises US$275M via 4.125% Convertible Notes with 25% Premium
ODV•
AVGO
Nvidia Predicts $91B Q3 Sales, Boosts Dividend and $80B Buyback; Broadcom Poised for AI Inference Growth
AVGO•
SVM
Silvercorp Secures 30-Year License Extension, Pays $60M for Tulkubash/Kyzyltash JV
SVM•
Sources
F